Association of high plasma TNF-alpha levels and TNF-alpha/IL-10 ratios with TNF2 allele in severe P. falciparum malaria patients in Sri lanka

Pathogens and Global Health

Volumn 107, Issue 1, 2013, Pages 21-29

  Perera, M K ^a   Herath, N P ^a,b   Pathirana, S L ^a   Phone Kyaw, M ^a,c   Alles, H K ^a   Mendis, K N ^a   Premawansa, S ^a,d   Handunnetti, S M ^a,d  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Department of Medical Research ^*  (Myanmar)

^d UNIVERSITY OF COLOMBO   (Sri Lanka)

Author keywords

Interleukin 10; P. falciparum; Severe malaria; Sri lanka; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BODY TEMPERATURE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; POLYMERASE CHAIN REACTION; SRI LANKA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INFANT; INTERLEUKIN-10; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; SRI LANKA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873563074     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000069     Document Type: Article

References (51)

1. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9(7):725-32.
2. Marsh K, Froster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, et al. Indicators of life threatening malaria in African children. N Engl J Med. 1995;332(21):1399-404.
3. Alles HK, Mendis KN, Carter R. Malaria mortality rates in South Asia and in Africa: implications for malaria control. Parasitol Today. 1998;14(9):369-75.
4. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005;77:171-90.
5. Normark J, Nilsson D, Ribacke U, Winter G, Moll K, Wheelock CE, et al. PfEMP1-DBL 1α amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proc Natl Acad Sci USA. 2007;104(40):15835-40.
6. Kyes SA, Kraemer SM, Smith JD. Antigenic variation in Plasmodium falciparum: gene organization and regulation of the var multigene family. Eukaryot Cell. 2007;6(9):1511-20.
7. Kwiatkowski D, Hill AV, Sambaou I, Twumasi P, Castracane J, Manogue KR, et al. TNF concentration in fatal cerebral, non-fatal cerebral and uncomplicated Plasmodium falciparum malaria. Lancet. 1990;336:1201-4.
8. Day PJ, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, et al. The prognostic and pathophysiologic role of pro- andanti-inflammatory cytokines in severe malaria. J Infect Dis. 1999;180:1288-97.
9. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, et al. Serum level of the proinflammatory cytokines interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12 (p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun. 2004;72(10):5630-7.
10. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of inflammatory cytokine release. Malar J. 2006;5:85.
11. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis. 1999;179:287-90.
12. Kwiatkowski D, Perlmann P. Inflammatory processes in the pathogenesis of malaria. In: Wahlgren M, Perlmann P, editors. Malaria: molecular and clinical aspects. 1st ed. Amsterdam: Harwood Academic Publishers; 1999, 329-361.
13. Ramharter M, Kremsner PG, Willheim M, Winkler H, Graninger W, Winkler S. Plasmodium falciparum-specific interleukin-2 and tumor necrosis factor-alpha expressing-T cells are associated with resistance to reinfection and severe malaria in healthy African children. Eur Cytokine Netw. 2004;15(3):189-96.
14. Allan RJ, Beattie P, Bate C, Hensbroek MB, Morris-Jones S, Greenwood BM, et al. Strain variation in tumor necrosis factor induction by parasites from children with acute falciparum malaria. Infect Immun. 1995;63(4):1173-5.
15. Wilson AG, di Giovine FS, Blackmore AI, Duff GW. Single base polymorphism in the human tumor necrosis factor alpha (TNF-α) gene detectable by Ncol restriction of PCR product. Hum Mol Genet. 1992;1(5):353.
16. Bouma G, Crusius, JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, et al. Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol. 1996;43:456-63.
17. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508-11.
18. Wattawidanage J, Carter R, Perera KL, Munasingha A, Bandara S, McGuinness D, et al. TNFα*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin Exp Immunol. 1999;115(2):350-5.
19. Li C, Corraliza I, Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect Immun. 1999;67(9):4435-42.
20. Ho M, White NJ. Molecular mechanisms of cytoadherence in malaria. Am J Physiol Cell Physiol. 1999;276:C1231-42.
21. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol. 2005;77:3-15.
22. Penman B, Gupta S. Evolution of virulence in malaria. J Biol. 2008;7:22.
23. Alles HK. Study of clinical aspects and pathophysiology of malaria and epidemiology of severe and complicated malaria [PhD thesis]. Colombo: University of Colombo; 1997.
24. Pathirana SL, Alles HK, Bandara S, Phone-Kyaw M, Perera MK, Wickramasinghe AR, et al. ABO-blood-group types and protection against severe, Plasmodium falciparum malaria. Ann Trop Med Parasitol. 2005;99(2):119-24.
25. Pathirana SL, Ekanayeke K, Howard RJ, Mendis KN, Handunnetti SM. Cytoadherence and its association with clinical disease in Plasmodium falciparum infections in Sri Lanka. J Natl Sci Found Sri Lanka. 2010;38(4):233-40.
26. Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. Trans Roy Soc Trop Med Hyg. 1990;84(Suppl. 2):1-65.
27. Karunaweera ND, Carter R, Grau GE, Mendis KN. Demonstration of anti-disease immunity to Plasmodium vivax malaria in Sri Lanka using a quantitative method to assess clinical disease. Am J Trop Med. 1998;58(2):204-10.
28. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
29. Sohail M, Kaul A, Bali P, Raziuddin M, Singh MP, Singh OP, et al. Alleles 2308A and 21031C in the TNF-α gene promoter do not increase the risk but associated with circulating levels of TNF-α and clinical features of vivax malaria in Indian patients. Mol Immunol. 2008;45:1682-92.
30. Perera RA. Peripheral blood mononuclear cells and cytokine Profile in severe and uncomplicated malaria patients in Sri-Lanka [PhD thesis]. Colombo: University of Colombo; 2003.
31. Herath NP. Human host genetic factors and cytokine responses associated with the pathogenesis of Plasmodium falciparum malarial disease [PhD thesis]. Colombo: University of Colombo; 2003.
32. Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med. 1989;320:1586-91.
33. Peyron F, Burdin N, Ringwald JP, Vuillez F, Rousset F, Banchereau J. High levels of circulating IL-10 in human malaria. Clin Exp Immunol. 1994;95:300-3.
34. Baptista JL, Vanham G, Wery M, Marck EV. Cytokine levels during mild and cerebral malaria in children living in a mesoendemic area. Trop Med Int Health. 1997;2(7):673-9.
35. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 2003;24 (9):491-9.
36. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, Frangos JA, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med. 2006;12(12):1417-22.
37. Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum TNF levels are closely associated during clinical paroxysms in P. vivax malaria. Proc Natl Acad Sci USA. 1992;89:3200-3.
38. Kern P, Hemmer CJ, van Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med. 1989;87(2):139-43.
39. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10: tumor necrosis factor (TNF)-α ratio is associated with TNF promoter variants and predicts malarial complications. J Infect Dis. 2000;182:1570-3.
40. Kwiatkowski D. Malarial toxins and the regulation of parasite density. Parasitol Today. 1995;11(6):206-12.
41. Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Greenwood BM. Tumour necrosis factor production in falciparum malaria and its association with schizont rupture. Clin Exp Immunol. 1989;77:361-6.
42. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and interleukin-10 receptor. Ann Rev Immunol. 2001;19:683-765.
43. Ho M, Schollaardt T, Snape S, Looareesuwan S, Suntharasamai P, White NJ. Endogenous interleukin-10 modulates pro-inflammatory response in Plasmodium falciparum malaria. J Infect Dis. 1998;178:520-5.
44. Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori DB, Oliver- Commey J, Nkrumah K, et al. Low plasma concentrations of interleukin-10 in severe malarial anemia compared with cerebral and uncomplicated malaria. Lancet. 1998;351(9118): 1768-72.
45. Awandare GA, Goka B, Boeuf P, Tetteh JK, Kurtzhals JA, Behr C, et al. Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis. 2006;194:1438-46.
46. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumara V. A low interleukin-10 tumor necrosis factor-α ratio is associated with malaria anemia in children residing in a holoendemic malaria region in Western Kenya. J Infect Dis. 1999;179:279-82.
47. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis. 2002;185:971-9.
48. Kumaratilleke LM, Ferrante A, Rzepczyk CM. The role of T lymphocytes in immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymphotoxin and IFN: comparisons with tumor necrosis factor effects. J Immunol. 1991;146(2):762-7.
49. Wozencraft AO, Dockrell HM, Taverne J, Targett GA, Playfare JH. Killing of human malaria parasites by macrophage secretory products. Infect Immun. 1984;43(2):664- 9.
50. Wilson AG, Gordon C, Di Giovine FS, de Vries N, van der Putte LB, Emery P, et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol. 1994;24(1):191-5.
51. Mergani A, Khamis AH, Haboor AB, Hashim E, Gumma M, Awadelseed B, et al. Lack of association between 2308 tumor necrosis factor polymorphism and susceptibility to cerebral malaria among Central Sudanese children. Int J Genetics and Mol Biol. 2010;2(5):67-71.